Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes

Xue-Jun Zhao, Eriko Koyama and Takashi Ishizaki
Drug Metabolism and Disposition July 1999, 27 (7) 776-785;
Xue-Jun Zhao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eriko Koyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Ishizaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This in vitro study was designed to identify the enzyme(s) involved in the two major metabolic pathways of rokitamycin [formations of leucomycin A7 (LMA7) from rokitamycin and of leucomycin V (LMV) from LMA7] and to assess possible drug interactions using human liver microsomes. Formation of LMA7 or LMV was NADPH-independent. Anti-rat NADPH cytochrome P-450 (CYP) reductase serum, specific inhibitors, or substrates of CYP isoforms showed no effects on the formation of LMA7 or LMV. The meanVmax andVmax/Km for the formation of LMA7 from rokitamycin were much greater (P < .01) than those for the formation of LMV from LMA7. Two esterase inhibitors, bis-nitro-phenylphosphate and physostigmine (100 μM), inhibited the formation of LMA7 or LMV by more than 85%, whereas no appreciable inhibition occurred by several substrates of carboxylesterase (EC 3.1.1.1). Except the moderate inhibition produced by promethazine and terfenadine, theophylline, mequitazine, chlorpheniramine, and diphenhydramine showed little or no inhibition for the formation of LMA7 or LMV. Rokitamycin, LMA7, LMV, erythromycin, and clarithromycin (up to 500 μM) had no appreciable inhibition for CYP1A2-, 2C9-, and 2D6-mediated catalytic reactions. However, rokitamycin, LMA7, erythromycin, and clarithromycin inhibited the CYP3A4-catalyzed triazolam α–hydroxylation with IC50(Ki) values of 5.8 (2.0), 40, 33 (20), and 56 (43) μM, respectively. It is concluded that the formations of LMA7 from rokitamycin and of LMV from LMA7 are catalyzed mainly by human esterase enzyme [possibly cholinesterase (EC3.1.1.8)]. However, whether rokitamycin would inhibit the CYP3A-mediated drug metabolism in vivo requires further investigations in patients.

Footnotes

  • Send reprint requests to: Dr. Takashi Ishizaki, M.D., Ph.D., Department of Pharmacology and Therapeutics, Graduate School of Clinical Pharmacy, Kumamoto University, Oe-honmachi 5–1, Kumamoto 862-0973, Japan.

  • ↵1 Current address: Department of Clinical Pharmacology, Research Institute, International Medical Center of Japan, Tokyo, Japan.

  • ↵2 Current address: Division of Clinical Pharmacology, Department of Medicine, Wishard Memorial Hospital, Indiana University School of Medicine, Indianapolis, IN 46202-2879.

  • ↵3 Current address: Department of Pharmacology and Therapeutics, Graduate School of Clinical Pharmacy, Kumamoto University, Oe-honmachi 5–1, Kumamoto 862-0973, Japan.

  • This study was supported by a grant-in-aid from the Ministry of Human Health and Welfare and by a postdoctoral fellowship training program from the Bureau of International Cooperation, International Medical Center of Japan (Tokyo, Japan).

  • Abbreviations used are::
    LMA7
    leucomycin A7
    LMV
    leucomycin V
    CYP
    cytochrome P-450
    BNPP
    bis-p-nitrophenyl phosphate
    SKF-525A
    2-diethylaminoethyl-2,2-diphenylvalterate
    FMO
    flavin-containing monooxygenase
    • Received October 29, 1998.
    • Accepted March 1, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (7)
Drug Metabolism and Disposition
Vol. 27, Issue 7
1 Jul 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes

Xue-Jun Zhao, Eriko Koyama and Takashi Ishizaki
Drug Metabolism and Disposition July 1, 1999, 27 (7) 776-785;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes

Xue-Jun Zhao, Eriko Koyama and Takashi Ishizaki
Drug Metabolism and Disposition July 1, 1999, 27 (7) 776-785;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipocyte PXR does not play an essential role in obesity.
  • CYP3A-mediated oxidation of DABE and BIBR0951
  • Biodistribution of Lipid in Rats
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics